-+ 0.00%
-+ 0.00%
-+ 0.00%

Axsome Therapeutics Signs Deal To Acquire Global Rights Of AZD7325 Novel Oral GABAA Receptor α2,3 From AstraZeneca

Benzinga·11/06/2025 12:12:05
Listen to the news

Axsome Therapeutics, Inc. (NASDAQ:AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it has entered into an agreement to obtain exclusive global rights to AZD7325, a novel oral GABAA receptor α2,3 subtype-selective positive allosteric modulator (PAM), licensed from AstraZeneca AB (NASDAQ:AZN). AZD7325 has completed Phase 1 trials. Axsome intends to evaluate AZD7325 as a potential treatment for epilepsy and plans to begin Phase 2 trial-enabling activities in 2026.

Under the terms of the License Amendment, AstraZeneca will receive a cash upfront payment in the single digit millions and is eligible to receive development and regulatory milestone payments for each indication, sales-based milestones, and a tiered mid-to-high single-digit royalty on potential global net sales of AZD7325.